TY - JOUR
T1 - TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration
AU - Gao, Ju
AU - Wang, L.
AU - Yan, Tingxiang
AU - Perry, George
AU - Wang, Xinglong
N1 - Funding Information:
Our research is supported by grants from the US National Institutes of Health ( 1R01NS089604 and 1R01AG056320 to X.W.) and the US Alzheimer’s Association ( AARG-17-499682 to X.W.).
Funding Information:
Our research is supported by grants from the US National Institutes of Health (1R01NS089604 and 1R01AG056320 to X.W.) and the US Alzheimer's Association (AARG-17-499682 to X.W.).
Publisher Copyright:
© 2019
PY - 2019/10
Y1 - 2019/10
N2 - Genetic mutations in TAR DNA-binding protein 43 (TDP-43) cause amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Importantly, TDP-43 proteinopathy, characterized by aberrant phosphorylation, ubiquitination, cleavage or nuclear depletion of TDP-43 in neurons and glial cells, is a common prominent pathological feature of various major neurodegenerative diseases including ALS, FTD, and Alzheimer's disease (AD). Although the pathomechanisms underlying TDP-43 proteinopathy remain elusive, pathologically relevant TDP-43 has been repeatedly shown to be present in either the inside or outside of mitochondria, and functionally involved in the regulation of mitochondrial morphology, trafficking, and function, suggesting mitochondria as likely targets of TDP-43 proteinopathy. In this review, we first describe the current knowledge of the association of TDP-43 with mitochondria. We then review in detail multiple mitochondrial pathways perturbed by pathological TDP-43, including mitochondrial fission and fusion dynamics, mitochondrial trafficking, bioenergetics, and mitochondrial quality control. Lastly, we briefly discuss how the study of TDP-43 proteinopathy and mitochondrial abnormalities may provide new avenues for neurodegeneration therapeutics.
AB - Genetic mutations in TAR DNA-binding protein 43 (TDP-43) cause amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Importantly, TDP-43 proteinopathy, characterized by aberrant phosphorylation, ubiquitination, cleavage or nuclear depletion of TDP-43 in neurons and glial cells, is a common prominent pathological feature of various major neurodegenerative diseases including ALS, FTD, and Alzheimer's disease (AD). Although the pathomechanisms underlying TDP-43 proteinopathy remain elusive, pathologically relevant TDP-43 has been repeatedly shown to be present in either the inside or outside of mitochondria, and functionally involved in the regulation of mitochondrial morphology, trafficking, and function, suggesting mitochondria as likely targets of TDP-43 proteinopathy. In this review, we first describe the current knowledge of the association of TDP-43 with mitochondria. We then review in detail multiple mitochondrial pathways perturbed by pathological TDP-43, including mitochondrial fission and fusion dynamics, mitochondrial trafficking, bioenergetics, and mitochondrial quality control. Lastly, we briefly discuss how the study of TDP-43 proteinopathy and mitochondrial abnormalities may provide new avenues for neurodegeneration therapeutics.
KW - Alzheimer's disease
KW - Amyotrophic lateral sclerosis
KW - Frontotemporal dementia
KW - Mitochondria
KW - Neurodegeneration
KW - Neurodegenerative diseases
KW - TDP-43
KW - TDP-43 proteinopathy
UR - http://www.scopus.com/inward/record.url?scp=85071262969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071262969&partnerID=8YFLogxK
U2 - 10.1016/j.mcn.2019.103396
DO - 10.1016/j.mcn.2019.103396
M3 - Review article
C2 - 31445085
AN - SCOPUS:85071262969
SN - 1044-7431
VL - 100
JO - Molecular and Cellular Neurosciences
JF - Molecular and Cellular Neurosciences
M1 - 103396
ER -